Latest Global Markets News

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.

Citigroup Global Markets Australia has announced a partially franked dividend of AUD 0.12 for the IAG CitiFirst Self-Funding Instalments, aligning key dates with IAG ordinary shares and reducing the outstanding loan balance.

Citigroup Global Markets Australia has announced the record and ex-dividend dates for the fully franked AUD 1.112 dividend on its ASX CitiFirst Instalment, signaling important timing for investors.

Citigroup Global Markets Australia has announced a fully franked dividend of AUD 1.112 for its CitiFirst Instalment MINI securities, with key dates set for February and March 2025.

Citigroup Global Markets Australia has announced a fully franked AUD 0.30 dividend for its ORG CitiFirst Instalments, with key dates set for early March 2025.

Citigroup Global Markets Australia has announced a fully franked dividend of AUD 0.30 for its ORG CitiFirst Instalment MINIs, aligning key dates with the ORG Ordinary shares. Investors should note the ex-dividend date on 4 March 2025 and the dividend payment expected on 28 March 2025.

Prophecy International Holdings has posted a record half-year revenue of $11.6 million for H1 FY25, driven by strong demand for its AI-enabled cybersecurity and data integration products. The company’s transition to subscription models and expansion into new global markets underpin a positive outlook.

Citigroup Global Markets Australia has announced a fully franked AUD 2.25 dividend for CBA CitiFirst Instalments, with trading turning ex-dividend on 19 February 2025. This aligns with the CBA Ordinary Security dividend schedule, offering investors synchronized payout timing.

Citigroup Global Markets Australia confirms a fully franked AUD 2.25 dividend for CBA CitiFirst Instalment MINIs, aligning key dates with CBA ordinary shares.

Neurotech International has inked a development deal with RH Farma to produce a pharmaceutical-grade cannabinoid drug targeting pediatric neurodevelopmental disorders, leveraging advanced European extraction technology.

Treasury Wine Estates delivered a robust 1H25 performance driven by luxury brands Penfolds and DAOU, offsetting softness in its premium and commercial portfolios. Despite strong earnings growth, the company lowers its full-year EBITS guidance, highlighting ongoing market headwinds.

Treasury Wine Estates has announced a 20-cent per share dividend for the half-year ending December 2024, accompanied by a fully franked component and an active Dividend Reinvestment Plan.